Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia

American Journal of Psychiatry

Volumn 160, Issue 1, 2003, Pages 13-23

  Kapur, Shitij ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

COGNITION; DELUSION; DRUG MECHANISM; HALLUCINATION; HUMAN; NEUROBIOLOGY; NEUROCHEMISTRY; PHENOMENOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RELAPSE; REVIEW; SCHIZOPHRENIA; SYMPTOM;

ANTIPSYCHOTIC AGENTS; BRAIN; COMBINED MODALITY THERAPY; DELUSIONS; DOPAMINE; HALLUCINATIONS; HUMANS; PERCEPTUAL DISTORTION; PSYCHOTHERAPY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0037223711     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.1.13     Document Type: Review

References (175)

1. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486
2. 2 receptors. Proc Natl Acad Sci USA 2000; 97:7673-7675
3. Seeman P: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1:133-152
4. Carlsson A, Lindquist M: Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-144
5. Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U: Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 1970; 11:303-314
6. van Rossum J: The significance of dopamine-receptor blockade for the action of neuroleptic drugs, in Neuropsychopharmacology: Proceedings of the 5th Collegium Internationale Neuropsychopharmacologicum. Edited by Brill H, Cole J, Deniker P, Hippius H, Bradley P. Amsterdam, Excerpta Medica, 1967, pp 321-329
7. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-719
8. Seeman P, Chau-Wong M, Tedesco J, Wong K: Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA 1975; 72:4376-4380
9. Farde L, Wiesel FA, Halldin C, Sedvall G: Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45:71-76
10. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects-a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33:227-235
11. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520
12. 2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient. Biol Psychiatry 2001; 50:873-883
13. Angrist B, Sathananthan G, Wilk S, Gershon S: Amphetamine psychosis: Behavioral and biochemical aspects. J Psychiatr Res 1974; 11:13-23
14. Angrist BM, Gershon S: The phenomenology of experimentally induced amphetamine psychosis - Preliminary observations. Biol Psychiatry 1970; 2:95-107
15. Harris D, Batki SL: Stimulant psychosis: Symptom profile and acute clinical course. Am J Addict 2000; 9:28-37
16. Angrist B, Rotrosen J, Gershon S: Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology (Berl) 1980; 67:31-38
17. Soares JC, Innis RB: Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 1999; 46:600-615
18. Laruelle M, Abi-Dargham A: Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol 1999; 13:358-371
19. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A: Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651-11654
20. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U, Salokangas RKR: Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346: 1130-1131
21. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL: Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 1997; 23:167-174
22. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B: Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46: 681-688
23. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93:9235-9240
24. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M: Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 1998; 155:761-767
25. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94:2569-2574
26. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97:8104-8109
27. Gjedde A, Wong DF: Quantification of neuroreceptors in living human brain, V: Endogenous neurotransmitter inhibition of haloperidol binding in psychosis. J Cereb Blood Flow Metab 2001; 21:982-994
28. 2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234:1558-1563
29. Wong DF, Pearlson GD, Tune LE, Young LT, Meltzer CC, Dannals RF, Ravert HT, Reith J, Kuhar MJ, Gjedde A: Quantification of neuroreceptors in the living human brain, IV: Effect of aging and elevations of D-2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997; 17:331-342
30. Andreasen NC, Carson R, Diksic M, Evans A, Farde L, Gjedde A, Hakim A, Lal S, Nair N, Sedvall G, et al: Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr Bull 1988; 14:471-484
31. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G: D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990; 47:213-219
32. Nordstrom AL, Farde L, Eriksson L, Halldin C: No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res Neuroimaging 1995; 61:67-83
33. Carlsson A, Hansson LO, Waters N, Carlsson ML: Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications. Life Sci 1997; 61:75-94
34. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R: Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 1999; 46:56-72
35. Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB: Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry 2000; 157:1108-1114
36. Pearlson GD, Wong DF, Tune LE, Ross CA, Chase GA, Links JM, Dannals RF, Wilson AA, Ravert HT, Wagner HN, Depaulo JR: In vivo D-2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995; 52:471-477
37. Wise RA: Neuroleptic attenuation of intracranial self-stimulation: Reward or performance deficits? Life Sci 1978; 22:535-542
38. Wise RA, Colle LM: Pimozide attenuates free feeding: Best scores analysis reveals a motivational deficit. Psychopharmacology (Berl) 1984; 84:446-451
39. Wise RA, Spindler J, deWit H, Gerberg GJ: Neuroleptic-induced "anhedonia" in rats: Pimozide blocks reward quality of food. Science 1978; 201:262-264
40. Markou A, Koob GF: Postcocaine anhedonia: An animal model of cocaine withdrawal. Neuropsychopharmacology 1991; 4: 17-26
41. Koob GF, Le Moal M: Drug abuse: Hedonic homeostatic dysregulation. Science 1997; 278:52-58
42. Gardner EL, Lowinson JH: Drug craving and positive-negative hedonic brain substrates activated by addicting drugs. Semin Neurosci 1993; 5:359-368
43. Wise RA: Neuroleptics and operant behavior: The anhedonia hypothesis. Behav Brain Sci 1982; 5:39-87
44. Salamone JD, Cousins MS, Snyder BJ: Behavioral functions of nucleus accumbens dopamine: Empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev 1997; 21:341-359
45. Salamone JD: The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav Brain Res 1994; 61:117-133
46. Blackburn JR, Phillips AG, Jakubovic A, Fibiger HC: Dopamine and preparatory behavior, II: A neurochemical analysis. Behav Neurosci 1989; 103:15-23
47. Schultz W, Apicella P, Scarnati E, Ljungberg T: Neuronal activity in monkey ventral striatum related to the expectation of reward. J Neurosci 1992; 12:4595-4610
48. Ljungberg T, Apicella P, Schultz W: Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol 1992; 67:145-163
49. Apicella P, Scarnati E, Schultz W: Tonically discharging neurons of monkey striatum respond to preparatory and rewarding stimuli. Exp Brain Res 1991; 84:672-675
50. Richardson NR, Gratton A: Behavior-relevant changes in nucleus accumbens dopamine transmission elicited by food reinforcement: An electrochemical study in rat. J Neurosci 1996; 16:8160-8169
51. Wenkstern D, Pfaus JG, Fibiger HC: Dopamine transmission increases in the nucleus accumbens of male rats during their first exposure to sexually receptive female rats. Brain Res 1993; 618:41-46
52. Lopez HH, Ettenberg A: Dopamine antagonism attenuates the unconditioned incentive value of estrous female cues. Pharmacol Biochem Behav 2001; 68:411-416
53. Berridge KC, Robinson TE: What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998; 28:309-369
54. Schultz W, Dayan P, Montague PR: A neural substrate of prediction and reward. Science 1997; 275:1593-1599
55. Schultz W: Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 1997; 7:191-197
56. Waelti P, Dickinson A, Schultz W: Dopamine responses comply with basic assumptions of formal learning theory. Nature 2001; 412:43-48
57. Redgrave P, Prescott TJ, Gurney K: Is the short-latency dopamine response too short to signal reward error? Trends Neurosci 1999; 22:146-151
58. Horvitz JC: Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 2000; 96: 651-656
59. Martin-Soelch C, Leenders KL, Chevalley AF, Missimer J, Kunig G, Magyar S, Mino A, Schultz W: Reward mechanisms in the brain and their role in dependence: Evidence from neurophysiological and neuroimaging studies. Brain Res Brain Res Rev 2001; 36:139-149
60. Di Chiara G: A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol 1998; 12:54-67
61. Bindra D: A motivational view of learning, performance, and behavior modification. Psychol Rev 1974; 81:199-213
62. Bindra D: How adaptive behaviour is produced: A perceptualmotivational alternative to response-reinforcement. Behavioural Brain Sciences 1978; 1:41-91
63. Toates F: The interaction of cognitive and stimulus-response processes in the control of behaviour. Neurosci Biobehav Rev 1998; 22:59-83
64. Fibiger HC, Phillips AG: Reward, motivation, cognition: Psychobiology of mesotelencephalic dopamine systems, in Handbook of Physiology, Section 1: The Nervous System, Vol 4: Intrinsic Regulatory Systems of the Brain. Edited by Bloom FE. New York, Oxford University Press, 1986, pp 647-675
65. Fibiger HC, Phillips AG: Mesocorticolimbic dopamine systems and reward. Ann NY Acad Sci 1988; 537:206-215
66. Robbins TW, Everitt BJ: Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 1996; 6:228-236
67. Robbins TW, Everitt BJ: Functional studies of the central catecholamines. Int Rev Neurobiol 1982; 23:303-365
68. Di Chiara G: Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 1999; 375:13-30
69. Panksepp J: Affective Neuroscience: The Foundations of Human and Animal Emotions. New York, Oxford University Press, 1998
70. Berridge KC: Pleasure, pain, desire and dread: Hidden core processes of emotion, in Well Being: The Foundations of Hedonic Psychology. Edited by Kahneman D, Diener E, Schwarz N. New York, Russell Sage Foundation, 1999, pp 525-557
71. Shizgal P: Neural basis of utility estimation. Curr Opin Neurobiol 1997; 7:198-208
72. Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: Past and current conceptualizations. Schizophr Bull 1996; 22:353-370
73. Bowers MB Jr, Freedman DX: "Psychedelic" experiences in acute psychoses. Arch Gen Psychiatry 1966; 15:240-248
74. Bowers MB Jr: Pathogenesis of acute schizophrenic psychosis: An experimental approach. Arch Gen Psychiatry 1968; 19:348-355
75. Roberts G: The origins of delusion. Br J Psychiatry 1992; 161: 298-308
76. Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman JA, Bracha SH, Ali SF: Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: The role of sensitization. Mol Psychiatry 1999; 4:512-523
77. Angrist B, Lee HK, Gershon S: The antagonism of amphetamine-induced symptomatology by a neuroleptic. Am J Psychiatry 1974; 131:817-819
78. David AS: Auditory hallucinations: Phenomenology, neuropsychology and neuroimaging update. Acta Psychiatr Scand Suppl 1999; 395:95-104
79. Bentall RP: The illusion of reality: A review and integration of psychological research on hallucinations. Psychol Bull 1990; 107:82-95
80. Grossberg S: How hallucinations may arise from brain mechanisms of learning, attention, and volition. J Int Neuropsychol Soc 2000; 6:583-592
81. Heinz A: [Anhedonia - A general nosology surmounting correlate of a dysfunctional dopaminergic reward system?]. Nervenarzt 1999; 70:391-398 (German)
82. McDonald N: Living with schizophrenia. Can Med Assoc J 1960; 82:218-221
83. An autobiography of a schizophrenic experience. J Abnorm Soc Psychiatry 1955; 51:677-680
84. Johns LC, van Os J: The continuity of psychotic experiences in the general population. Clin Psychol Rev 2001; 21:1125-1141
85. van Os J, Hanssen M, Bijl RV, Vollebergh W: Prevalence of psychotic disorder and community level of psychotic symptoms: An urban-rural comparison. Arch Gen Psychiatry 2001; 58:663-668
86. Heinrich RW: In Search of Madness: Schizophrenia and Neuroscience. Oxford, UK, Oxford University Press, 2001
87. Tsuang MT, Stone WS, Faraone SV: Toward reformulating the diagnosis of schizophrenia. Am J Psychiatry 2000; 157:1041-1050
88. Faraone SV, Green Al, Seidman LJ, Tsuang MT: "Schizotaxia": Clinical implications and new directions for research. Schizophr Bull 2001; 27:1-18
89. Walker EF, Grimes KE, Davis DM, Smith AJ: Childhood precursors of schizophrenia: Facial expressions of emotion. Am J Psychiatry 1993; 150:1654-1660
90. Ellison Z, van Os J, Murray R: Special feature: Childhood personality characteristics of schizophrenia: Manifestations of, or risk factors for, the disorder? J Personal Disord 1998; 12:247-261
91. Rabinowitz J, Reichenberg A, Weiser M, Mark M, Kaplan Z, Davidson M: Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital: Cross-sectional analysis. Br J Psychiatry 2000; 177:26-32
92. Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H: Children's self-reported psychotic symptoms and adult schizophreniform disorder: A 15-year longitudinal study. Arch Gen Psychiatry 2000; 57:1053-1058
93. Cannon M, Walsh E, Hollis C, Kargin M, Taylor E, Murray RM, Jones PB: Predictors of later schizophrenia and affective psychosis among attendees at a child psychiatry department. Br J Psychiatry 2001; 178:420-426
94. Garety PA, Hemsley DR, Wessely S: Reasoning in deluded schizophrenic and paranoid patients: Biases in performance on a probabilistic inference task. J Nerv Ment Dis 1991; 179: 194-201
95. Freeman D, Garety PA, Kuipers E: Persecutory delusions: Developing the understanding of belief maintenance and emotional distress. Psychol Med 2001; 31:1293-1306
96. Bentall RP, Kinderman P, Kaney S: The self, attributional processes and abnormal beliefs: Towards a model of persecutory delusions. Behav Res Ther 1994; 32:331-341
97. Bentall RP, Corcoran R, Howard R, Blackwood N, Kinderman P: Persecutory delusions: A review and theoretical integration. Clin Psychol Rev 2001; 21:1143-1192
98. Frith CD, Blakemore S, Wolpert DM: Explaining the symptoms of schizophrenia: Abnormalities in the awareness of action. Brain Res Brain Res Rev 2000; 31:357-363
99. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC: Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol 1994; 103:171-183
100. Miller R: The time course of neuroleptic therapy for psychosis: Role of learning processes and implications for concepts of psychotic illness. Psychopharmacology (Berl) 1987; 92:405-415
101. Kuhar MJ, Joyce AR: Slow onset of CNS drugs: Can changes in protein concentration account for the delay? Trends Pharmacol Sci 2001; 22:450-456
102. Lewander T: Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 1994; 380:8-13
103. King DJ, Burke M, Lucas RA: Antipsychotic drug-induced dysphoria. Br J Psychiatry 1995; 167:480-482
104. Gerlach J, Larsen EB: Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl 1999; 395:113-117
105. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43:135-145
106. Gilbert PL, Harris MJ, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Arch Gen Psychiatry 1995; 52:173-188
107. Kapur S, Seeman P: Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001; 158:360-369
108. Strange PG: Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53:119-133
109. Courvoisier S: Pharmacodynamic basis for the use of chlorpromazine in psychiatry. Q Rev Psychiatry Neurol 1956; 17:25-37
110. Dews PB, Morse WH: Behavioural pharmacology. Annu Rev Pharmacol 1961; 1:145-174
111. Johnson FN: Stimulus significance and chlorpromazine effects on the expression of avoidance learning in mice. Neuropharmacology 1971; 10:267-272
112. Johnson FN: Stimulus significance and chlorpromazine-induced impairment of avoidance learning in mice. Neuropharmacology 1971; 10:9-14
113. Clody DE, Carlton PL: Stimulus efficacy, chlorpromazine, and schizophrenia. Psychopharmacology (Berl) 1980; 69:127-131
114. Killcross AS, Everitt BJ, Robins TW: Symmetrical effects of amphetamine and alpha-flupenthixol on conditioned punishment and conditioned reinforcement: Contrasts with midazolam. Psychopharmacology (Berl) 1997; 129:141-152
115. Crow TJ: Catecholamine reward pathways and schizophrenia: The mechanism of the antipsychotic effect and the site of the primary disturbance. Fed Proc 1979; 38:2462-2467
116. Laborit H, Huguenard P: L'hibernation artificielle par moyens pharmacodynamiques et physiques. Presse Med 1951; 59: 1329
117. Delay J, Deniker P, Harl J: Traitment des états d'excitation et d'agitation par une méthode médicamenteuse dérivée de l'hibernothérapie. Ann Med Psychol 1952; 110:267-273
118. Meurice E: [The effect of neuroleptics in a attempt at understanding the vulnerability to schizophrenia]. Acta Psychiatr Belg 1992; 92:339-354 (French)
119. Belmaker RH, Wald D: Haloperidol in normals. Br J Psychiatry 1977; 131:222-223
120. Miller R: Hyperactivity of associations in psychosis. Aust NZ J Psychiatry 1989; 23:241-248
121. Winkelman NW: Chlorpromazine in the treatment of neuropsychiatric disorders. JAMA 1954; 155:18-21
122. Elkes J, Elkes C: Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients. Br Med J 1954; 2: 560-565
123. Opler LA, Kay SR, Lindenmayer JP, Fisxbein A: Structured Clinical Interview for the Positive and Negative Symptom Scale. Toronto, Multi-Health Systems, 1992
124. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
125. Chouinard G, Miller R: A rating scale for psychotic symptoms (RSPS), part I: Theoretical principles and subscale 1: Perception symptoms (illusions and hallucinations). Schizophr Res 1999; 38:101-122
126. Harrow M, Silverstein ML: Psychotic symptoms in schizophrenia after the acute phase. Schizophr Bull 1977; 3:608-616
127. Harrow M, MacDonald AW III, Sands JR, Silverstein ML: Vulnerability to delusions over time in schizophrenia and affective disorders. Schizophr Bull 1995; 21:95-109
128. Hole RW, Rush AJ, Beck AT: A cognitive investigation of schizophrenic delusions. Psychiatry 1979; 42:312-319
129. Levy ST, McGlashan TH, Carpenter WT Jr: Integration and sealing-over as recovery styles from acute psychosis. J Nerv Ment Dis 1975; 161:307-312
130. McGlashan TH, Levy ST, Carpenter WT Jr: Integration and sealing over: Clinically distinct recovery styles from schizophrenia. Arch Gen Psychiatry 1975; 32:1269-1272
131. Drayton M, Birchwood M, Trower P: Early attachment experience and recovery from psychosis. Br J Clin Psychol 1998; 37(part 3):269-284
132. Sacks MH, Carpenter WT Jr, Strauss JS: Recovery from delusions: Three phases documented by patient's interpretation of research procedures. Arch Gen Psychiatry 1974; 30:117-120
133. Nuechterlein GK, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158:1835-1842
134. Kapur S, Remington G: Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001; 52:503-517
135. Janowsky DS, Davis JM: Methylphenidate, dextroamphetamine, and levamfetamine: Effects on schizophrenic symptoms. Arch Gen Psychiatry 1976; 33:304-308
136. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A: Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 1997; 42: 664-668
137. Angrist B, Rotrosen J, Gershon S: Differential effects of amphetamine and neuroleptics on negative vs positive symptoms in schizophrenia. Psychopharmacology (Berl) 1980; 72:17-19
138. Angrist B, Thompson H, Shopsin B, Gershon S: Clinical studies with dopamine-receptor stimulants. Psychopharmacologia 1975; 44:273-280
139. Wilson EO: Consilience: The Unity of Knowledge. New York, Vintage, 1999
140. Miller R: Major psychosis and dopamine: Controversial features and some suggestions. Psychol Med 1984; 14:779-789
141. Garety PA, Freeman D: Cognitive approaches to delusions: A critical review of theories and evidence. Br J Clin Psychol 1999; 38(part 2):113-154
142. Gould RA, Mueser KT, Bolton E, Mays V, Goff D: Cognitive therapy for psychosis in schizophrenia: An effect size analysis. Schizophr Res 2001; 48:335-342
143. Garety P: Delusions: Problems in definition and measurement. Br J Med Psychol 1985; 58(part 1):25-34
144. Naber D: A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10(suppl 3):133-138
145. Van Putten T, Marder SR: Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987; 48(Sept suppl):13-19
146. McCartan D, Bell R, Green JF, Campbell C, Trimble K, Pickering A, King DJ: The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers. J Psychopharmacol 2001; 15:96-104
147. Acquas E, Carboni E, Leone P, Di Chiara G: SCH 23390 blocks drug-conditioned place-preference and place-aversion: Anhedonia (lack of reward) or apathy (lack of motivation) after dopamine-receptor blockade? Psychopharmacology (Berl) 1989; 99:151-155
148. Killcross AS, Dickinson A, Robbins TW: Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: Evidence for dopamine-reinforcer interactions. Psychopharmacology (Berl) 1994; 115: 196-205
149. Killcross S, Robbins TW, Everitt BJ: Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala. Nature 1997; 388:377-380
150. Ettenberg A: Dopamine, neuroleptics and reinforced behavior. Neurosci Biobehav Rev 1989; 13:105-111
151. Fonberg E: Chlorpromazine exerts stronger suppressive action on the instrumental responses motivated by social than by alimentary reward. Acta Neurobiol Exp 1992; 52:57-69
152. Boye S, Rompre P-P: Behavioural evidence of depolarization block of dopamine neurons after chronic treatment with haloperidol and clozapine. J Neurosci 2000; 20:1-11
153. Phillips P, Johnson S: How does drug and alcohol misuse develop among people with psychotic illness? A literature review. Soc Psychiatry Psychiatr Epidemiol 2001; 36:269-276
154. Voruganti LN, Heslegrave RJ, Awad AG: Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185:463-465
155. Mueser KT, Drake RE, Wallach MA: Dual diagnosis: A review of etiological theories. Addict Behav 1998; 23:717-734
156. Grace AA: Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24
157. Javitt DC: Glutamate receptors and schizophrenia: Opportunities and caveats. Mol Psychiatry 1996; 1:16-17
158. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158:1367-1377
159. Weinberger DR: On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Neuropsychopharmacology 1996; 14(3 suppl):1S-11S
160. Harrison PJ: Schizophrenia: A disorder of neurodevelopment? Curr Opin Neurobiol 1997; 7:285-289
161. Keshavan MS: Development, disease and degeneration in schizophrenia: A unitary pathophysiological model. J Psychiatr Res 1999; 33:513-521
162. Hamm AO, Weike Al, Schupp HT: The effect of neuroleptic medication on prepulse inhibition in schizophrenia patients: Current status and future issues. Psychopharmacology (Berl) 2001; 156:259-265
163. Braff DL, Geyer MA, Swerdlow NR: Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 2001; 156:234-258
164. Parwani A, Duncan EJ, Bartlett E, Madonick SH, Efferen TR, Rajan R, Sanfilipo M, Chappell PB, Chakravorty S, Gonzenbach S, Ko GN, Rotrosen JP: Impaired prepulse inhibition of acoustic startle in schizophrenia. Biol Psychiatry 2000; 47:662-669
165. Feldon J, Weiner I: From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiatr Res 1992; 26:345-366
166. Grace AA: Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 2000; 31:330-341
167. Braff DL, Geyer MA: Sensorimotor gating and schizophrenia: Human and animal model studies. Arch Gen Psychiatry 1990; 47:181-188
168. Kendler KS: A psychiatric dialogue on the mind-body problem. Am J Psychiatry 2001; 158:989-1000
169. Gabbard GO: Mind and brain in psychiatric treatment. Bull Menninger Clin 1994; 58:427-446
170. Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr: A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001; 58:165-171
171. Peralta V, Cuesta MJ: How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res 2001; 49:269-285
172. Andreasen NC, Nopoulos P, O'Leary DS, Miller DD, Wassink T, Flaum M: Defining the phenotype of schizophrenia: Cognitive dysmetria and its neural mechanisms. Biol Psychiatry 1999; 46:908-920
173. Johnstone EC, Crow TJ, Frith CD, Owens DG:The Northwick Park "functional" psychosis study: Diagnosis and treatment response. Lancet 1988; 2:119-125
174. Carlsson A, Waters N, Waters S, Carlsson ML: Network interactions in schizophrenia - Therapeutic implications. Brain Res Brain Res Rev 2000; 31:342-349
175. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML: Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 2001; 41:237-260